Date: 2014-06-30
Type of information: Services contract
Compound: HiSeq 2500 and consumables to develop and perform non-invasive prenatal testing (NIPT)
Company: Illumina (USA -CA) Biomnis (France)
Therapeutic area: Technology - Services
Type agreement: services
Action mechanism:
Disease:
Details: * On June 30, 2014, Illumina announced that it has entered into an agreement with Biomnis under which the company will use the HiSeq 2500 and consumables from Illumina to develop and perform non-invasive prenatal testing (NIPT). Biomnis plans to make NIPT available in France. "Biomnis evaluated the different technologies and selected Illumina because of their high level of performance as published in respected, peer-reviewed medical journals,\" said Dr. Charles Woler, CEO of Biomnis Laboratories. "Backed by whole genome sequencing, we look forward to making our highly accurate test accessible to physicians and their patients."
Financial terms:
Latest news:
